Clinical Trials Browser

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Neoplasms

NCT06211764 2026-03-17

SunRISe-5

Phase 3 Active not recruiting

272 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07322263 2026-03-17

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Phase 2 Not yet recruiting

174 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT04452591 2026-03-16

BOND-003

Phase 3 Active not recruiting

190 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT06995677 2026-03-16

SURF302

Phase 2 Recruiting

90 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07474519 2026-03-16

Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer

Phase 4 Recruiting

40 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT05316155 2026-03-13

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Phase 1/2 Recruiting

235 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06173349 2026-03-13

PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer

Phase 1 Recruiting

12 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06319820 2026-03-13

MoonRISe-1

Phase 3 Recruiting

641 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06919965 2026-03-13

MoonRISe-3

Phase 3 Recruiting

220 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07309445 2026-03-13

Nova-sTAR

Recruiting

150 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07206225 2026-03-11

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

Phase 1 Recruiting

294 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07464145 2026-03-11

RESCUE

Phase 3 Not yet recruiting

393 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Neoplasms, Urologic Neoplasms

NCT06443944 2026-03-06

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Available

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT07000084 2026-03-04

GAIN-BCG

Phase 3 Recruiting

330 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07130578 2026-03-03

The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer

Recruiting

60 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07445308 2026-03-03

The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.

Phase 1/2 Not yet recruiting

120 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT05538663 2026-03-02

BRIDGE

Phase 3 Active not recruiting

870 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04172675 2026-02-24

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Phase 2 Completed

107 enrolled 17 charts

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07424287 2026-02-20

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Phase 3 Not yet recruiting

236 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06637423 2026-02-19

TroFuse-027

Phase 1/2 Recruiting

32 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06026332 2026-02-17

ABLE-41

Terminated

202 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Clinical Trials

ADVANCED-3

SunRISe-5

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

BOND-003

SURF302

Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer

MoonRISe-1

MoonRISe-3

Nova-sTAR

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

RESCUE

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

GAIN-BCG

The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer

The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.

BRIDGE

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

TroFuse-027

ABLE-41